Humira patents take center stage as House panel targets AbbVie pricing

cafead

Administrator
Staff member
  • cafead   May 18, 2021 at 11:32: PM
via Patents protecting AbbVie's inflammatory disease drug Humira in Europe expired two and half years ago, forcing the company to sharply cut its prices as low-cost competitors flooded the region.

article source